Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candin Challenge Validation with Secukinumab (PLATFORM)
NCT04589026Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of secukinumab in psoriasis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Presence and Size of Induration at Candin Injection Site at Day 8. Started Oct 2020; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04589026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589026.